Advanced Biotherapy Inc., of Woodland Hills, Calif., was issued U.S. Patent No. 6,333,032 for the exclusive use of interferon-gamma antibodies, including humanized and fully human, as well as other antibody types to treat multiple sclerosis.
Alteon Inc., of Ramsey, N.J., was issued U.S. Patent No. 6,326,396 titled “Glucose and Lipid Lowering Compounds” for a new class of orally available glucose-lowering agents that significantly lower blood glucose levels and free fatty acids in preclinical models of Type II diabetes.
Cellegy Pharmaceuticals Inc., of South San Francisco, was issued U.S. Patent No. 6,319,913 titled “Penetration Enhancing and Irritation Reducing Systems,” covering methods of topically administering sex hormones.
CellExSys Inc., a majority owned subsidiary of Targeted Genetics Corp., of Seattle, was issued U.S. Patent No. 6,316,257 titled “Modified Rapid Expansion Methods for In Vitro Propagation of T Lymphocytes.”
Cepheid Inc., of Sunnyvale, Calif., was issued U.S. Patent No. 6,312,929 broadly covering compositions and methods that ensure, with a single, closed reaction-tube, the integrity of all the chemical reagents used for PCR-based DNA detection.
Cortex Pharmaceuticals Inc., of Irvine, Calif., was issued U.S. Patent No. 6,274,600 titled “Heteroatom Substituted Benzoyl Derivatives that Enhance Synaptic Responses Mediated by AMPA Receptors.” Cortex also was issued a notice of allowance for an application titled “Endocrine Modulation with Positive Modulators of AMPA Type Glutamate Receptors.”
Cubist Pharmaceuticals Inc., of Lexington, Mass., was issued a notice of allowance from the U.S. Patent and Trademark Office for an application titled “Methods for Administration of Antibiotics,” which would provide exclusivity for Cubist’s investigational antibiotic Cidecin (daptomycin for injection) until at least 2019, should it be approved by the FDA.
Epoch Biosciences Inc., of Bothell, Wash., was issued U.S. Patent No. 6,312,894 on “Hybridization and Mismatch Discrimination using Oligonucleotides Conjugated to Minor Groove Binders.”
Genentech Inc., of South San Francisco, was issued U.S. Patent No. 6,331,415 relating to fundamental methods and compositions used to produce antibodies by recombinant DNA technology.
Genteric Inc., of Alameda, Calif., was awarded U.S. Patent No. 6,316,421 titled “Pentaerythritol Lipid Derivates and Nucleic-Acid Complexes.”